Amr Salahieh, Chair
AKURA MEDICAL'S STORY
Next-generation clot removal
With an estimated 900,000 cases and 100,000 deaths annually in the United States, venous thromboembolism is the third most common cardiovascular cause of death, trailing only heart attacks and strokes. Existing treatments have significant limitations and requirements – high bleeding risks, lengthy treatment times, procedural complexities and extended hospital stays.
Akura Medical's flagship product — the Akura Thrombectomy Catheter System — offers a unique solution that aims to address four key limitations of current-generation devices, namely navigation, target clot visualization, catheter clogging and tracking case progress.
Boasting a low-profile, steerable sheath, this user-friendly system incorporates bidirectional steering designed to enable physicians to precisely navigate complex vasculature. Physicians can deliver a small dose of contrast at any time during the procedure to visualize the area of interest and address clots without the need to cross them.
"The investment by and partnership with Unorthodox Ventures will support our submission for FDA clearance of our differentiated platform, clinical trials for additional indications and scaling manufacturing capabilities. We look forward to working with Carey Smith and his team to bring this innovative solution to market and meaningfully change how physicians treat venous thromboembolism."
— Amr Salahieh, Chair
Akura Medical in the Media
Fierce Biotech – Akura Medical Raises $60M
OUR APPROACH
We invest in early-stage startups all around the world, often helping overseas companies open their first American offices. Click below to tell us about your work.
Contact Us →